CVS Health Corp. expects to administer 70% to 80% fewer COVID-19 vaccines in 2022 compared with 2021, adding that in-store diagnostic testing could fall 40% to 50%.

Britain’s GSK forecast growth in 2022 after racking up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, beating quarterly forecasts in the company’s first earnings report since rejecting Unilever’s bid for GlaxoSmithKline’s consumer arm.

Pfizer Inc. expects 2022 sales of its COVID-19 vaccine and antiviral pill to top $54 billion, but that fell short of lofty Wall Street estimates and the biopharmaceutical company’s shares were off about 3 percent.

Amgen posted a 3 percent rise in total 2021 fourth-quarter revenue to $6.8 billion and a 2 percent increase in total revenue for the year to $26 billion, driven mainly through wins from “other” gains. 

Johnson & Johnson on Jan. 25 forecast as much as $3.5 billion in sales of the company’s COVID-19 vaccine in 2022, a 46% jump for the shot that has fared poorly compared to rivals. Additionally, J&J plans to take a more aggressive stance on deals for the company’s medical device unit.

Eli Lilly and Company’s projections for next year exceed Wall Street projections for the drug manufacturer, predicting 2022 revenue of $27.8 billion to $28.3 billion.

CVS Health Corp. will shut about 900 stores over the next three years as the company tries to adapt to changing consumer preferences by pivoting to new store formats that offer more health services.

AstraZeneca reported Covid-19 vaccine sales of $1.05 billion for third-quarter 2021, with Vaxzevria contributing 1 percent to the company’s profit for the quarter.

Moderna Inc. on Nov. 4 slashed the 2021 sales forecast for the company’s Covid-19 vaccine by as much as $5 billion, grappling to fill vials and distribute them to meet unprecedented world demand, sending its shares tumbling 16 percent.

Amgen Chairman and Chief Executive Officer Robert Bradway anticipates the non-small cell lung cancer drug Lumakras will become a cornerstone medicine as the company aims to develop multiple medications for targets long thought to be undruggable.